ongoing

STRIVE will evaluate the use of adjunctive, low-dose intracoronary tissue plasminogen activator during primary percutaneous coronary intervention (PCI) for patients with ST elevation myocardial infarction (STEMI) in reducing major adverse cardiovascular events.

STRIVE will assess the efficacy of a novel approach to prevent and treat microvascular obstruction and reduce major cardiovascular events using intracoronary administration of very low-dose fibrinolytic (tissue plasminogen activator, tPA) directly into the culprit coronary artery during primary PCI.

The objective is to determine if low-dose adjunctive intracoronary tPA (10 mg or 20 mg) will reduce the incidence of post-procedural myocardial blush (MBG) grade 0/1 or distal embolization in patients undergoing primary PCI for STEMI.

Download Presentation PDF
Study Type

Interventional - Drug

Study Design

Prospective 3-arm parallel group, open label RCT

NO. of Countries

1

NO. of Sites

5 target

NO. of Participants

200 target

Study Period

2018-2020

Sponsor

PHRI

Heart & Stroke Foundation

Back To Top